CoChat
Sign Up
Cited by 126Treatment of Major DepressionSuicide and Self-Harm StudiesElectroconvulsive Therapy Studies

The DOI matches its Crossref record, with a small difference in title or year.

Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study

Ionescu, Dawn F., Swee, Michaela B., Pavone, Kara J., Taylor, Norman, Akeju, Oluwaseun, Baer, Lee, Nyer, Maren, Cassano, Paolo, Mischoulon, David, Alpert, Jonathan E., Brown, Emery N., Nock, Matthew K., Fava, Maurizio, Cusin, Cristina·2016·The Journal of Clinical Psychiatry
DOI 10.4088/jcp.15m10056
Open this paper in CoChat — free account

Abstract

BACKGROUND: Ketamine rapidly reduces thoughts of suicide in patients with treatment-resistant depression who are at low risk for suicide. However, the extent to which ketamine reduces thoughts of suicide in depressed patients with current suicidal ideation remains unknown. METHODS: Between April 2012 and October 2013, 14 outpatients with DSM-IV-diagnosed major depressive disorder were recruited for the presence of current, stable (≥ 3 months) suicidal thoughts. They received open-label ketamine infusions over 3 weeks (0.5 mg/kg over 45 minutes for the first 3 infusions; 0.75 mg/kg over 45 minutes for the last 3). In this secondary analysis, the primary outcome measures of suicidal ideation (Columbia-Suicide Severity Rating Scale [C-SSRS] and the Suicide Item of the 28-item Hamilton Depression Rating Scale [HDRS₂₈-SI]) were assessed at 240 minutes postinfusion and for 3 months thereafter in a naturalistic follow-up. RESULTS: Over the course of the infusions (acute treatment phase), 7 of 14 patients (50%) showed remission of suicidal ideation on the C-SSRS Ideation scale (even among patients whose depression did not remit). There was a significant linear decrease in this score over time (P < .001), which approached significance even after controlling for severity of 6-item Hamilton Depression Rating Scale (HDRS₆) core depression items (P = .05). Similarly, there were significant decreases in the C-SSRS Intensity (P < .01) and HDRS₂₈-SI (P < .001) scores during the acute treatment phase. Two of the 7 patients who achieved remission during the acute treatment phase (29%) maintained their remission throughout a 3-month naturalistic follow-up. CONCLUSIONS: In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01582945.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.15m10056

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

Sorted by citations

Items 101–126 of 126

Related

See all

Metadata

Authors
Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., Nyer, M., Cassano, P., Mischoulon, D., Alpert, J. E., Brown, E. N., Nock, M. K., Fava, M., & Cusin, C.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
ORCID
Venue
The Journal of Clinical Psychiatry
Publisher
Physicians Postgraduate Press, Inc
Published
2016-05-10
Volume
77
Issue
06
Pages
e719-e725
ISSN
0160-6689 (ISSN-L)
DOI
10.4088/jcp.15m10056
OpenAlex
W2346471661
Cited by
126
References
0
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 12 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 12 · 2018: 29 · 2017: 15 · 2016: 2
FWCI
15.66
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, suicidal ideation, major depressive disorder, treatment-resistant depression, intravenous ketamine infusion, suicide prevention, remission maintenance, Columbia Suicide Severity Rating Scale, Hamilton Depression Rating Scale
MeSH terms
Adolescent, Adult, Aged, Major Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Remission Induction, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review